Objective: To investigate the effect and the mechanism of Shenfu injection (SFI, ) on the resuscitation from general anesthesia . Methods: Forty patients who received selective abdominal surgery with general anesthesi...Objective: To investigate the effect and the mechanism of Shenfu injection (SFI, ) on the resuscitation from general anesthesia . Methods: Forty patients who received selective abdominal surgery with general anesthesia for 3-4 hrs and ASA grade Ⅰ-Ⅱ were divided into two groups, the trial group and the control group, 20 patients in each group. After being sent into the postanesthesia care unit (PACU), the trial group was treated with intravenous dripping of SFI 1.0 ml/kg and the control group was treated with intravenous dripping of equal volume of normal saline. All patients were observed in double blindly manner, the self ventilation recovery time, extubation time, the time of leaving PACU and their Glasgow coma scale (GCS) were recorded and compared. 2 ml of peripheral venous blood were taken to determine the plasma β-endorphin (β-EP) content at the time points of before (T1), 5min (T2), 15min (T3) and 30 min (T4) after dripping. Results: The self ventilation recovery time, extubation time and time of leaving PACU in the trial group were all shorter than those in the control group (P<0 01), the GCS in the trial group was better than that in the control group (P<0 01). The plasma content of β-EP raised gradually along the recovering of patients consciousness, as compared with the content before dripping (T1), it showed insignificant difference at time point T2 but significant difference at T3 and T4, comparison at the corres ponding time point showed that the content at T1 and T2 were similar in the two groups (P>0 05), but at T3 and T4, the content was higher in the trial group than that in the control group respectively (P<0 01). There was insignificant difference between T1 and before treatment ( P>0 05), but significant difference was found when compared T3, T4 and before treatment (P<0 01).Conclusion: SFI could accelerate the resuscitation after general anesthesia, the mechanism may be related with its action in raising plasma β-EP level.展开更多
Objective: to analyze the clinical treatment of benign prostatic hyperplasia (BPH) symptoms and explore the efficacy of different surgical methods. Methods: during the study period, 82 male patients diagnosed and trea...Objective: to analyze the clinical treatment of benign prostatic hyperplasia (BPH) symptoms and explore the efficacy of different surgical methods. Methods: during the study period, 82 male patients diagnosed and treated in the prostate department of our hospital were included as clinical analysis cases. The start time of the study was from April 2021. The data needed during the clinical study period were collected, and the relevant research plan was drawn up until April 2022. The selected patients were divided into groups according to their treatment methods. The number of patients in each group was 41:41, of which the control group was given plasma electrotomy and the study group was given plasma enucleation. The complications, clinical indexes, quality of life, urodynamics and ILEF-5 were compared between the two groups. Results: compared with the two groups, the quality of life in the study group was higher. Compared with the two groups, the control group had more complications. Compared with the urodynamic indexes of the two groups, the PVR index of the control group was (40.05 ± 3.69), the VMCC index was (337.36 ± 25.39), the Qmax index was (21.95 ± 1.24), the PVR index of the study group was (42.35 ± 4.22), the VMCC index was (349.54 ± 25.48), and the Qmax index was (23.25 ± 1.07), P < 0.05. Comparison of sexual function and erectile function scores between the two groups: the preoperative index of the study group was (24.58 ± 5.59) compared with that of the control group (23.97 ± 5.47), and there was no statistical significance, P > 0.05. After treatment, the index of the control group was (16.24 ± 5.47) compared with that of the study group (20.55 ± 5.69), and the score of the control group was lower. Compared with the clinical indexes of the two groups, the indexes of the control group were worse, P < 0.05. Conclusion: during the clinical treatment of benign prostatic hyperplasia, the patients were treated with different operations, and good results were achieved. During the treatment of plasma enucleation, the clinical related index were excellent.展开更多
CONSPECTUS:Hydrogen medicine materials are defined as a new concept of biomedical materials specifically engineered to overcome critical challenges in hydrogen medicine,including exploration of biological effects and ...CONSPECTUS:Hydrogen medicine materials are defined as a new concept of biomedical materials specifically engineered to overcome critical challenges in hydrogen medicine,including exploration of biological effects and mechanisms of H2 by in vivo monitoring of H2 transportation,metabolism and transformation,enhancement of H2 therapeutic efficacy against various oxidative stress-related diseases by high-efficiency and site-specific delivery and controlled release of H2,etc.As the smallest and weakly reductive molecule,H2 exhibits some unique biological characteristics,including high tissue permeability,antioxidative stress(OS),anti-inflammation,antiapoptosis,antisenescence,pro-regeneration/pro-self-repairing,anticancer,antibiofilm,high bio-compatibility,and biosafety,holding a high value of biomedical applications.However,the related biological mechanisms are not very clear.Typically,multifaceted biological behaviors of H2 in varied pathological microenvironments,such as inflammation,cancer,and injured tissue,have not been well elucidated.Moreover,as a therapeutic agent,the pharmacokinetics of H2,involving absorption,biodistribution,metabolism,and excretion,has to be clarified before clinical application,which needs the development of hydrogen bioprobes to resolve.Based on high biosafety and therapeutic validity of H2,both hydrogen gas inhalator and hydrogen-rich water generator have been clinically approved for adjuvant therapy of some respiratory and digestive system diseases including chronic obstructive pulmonary disease(COPD),hyperuricemia,hyperlipemia,gastrelcosis and coprostasis,but they hardly realize effective delivery toward remote diseased focuses.Therefore,efficient,site-specific and controlled/sustained H2-delivering materials with high biosafety urgently need to be developed for improving the outcome of hydrogen therapy.Based on these unique advantages and unsolved key issues in hydrogen medicine,hydrogen medicine materials as an emerging interdisciplinary field have attracted increasing attention in recent years.In this Account,we present a brief overview of the recent advances of hydrogen medicine materials including hydrogen bioprobes and hydrogen-delivering materials(hydrogen carriers,hydrolytic hydrogen-generating materials,and catalytic hydrogen-generating materials),as well as their typical biomedical applications including targeted inflammation therapy,targeted tumor therapy,and local tissue repair/regeneration.Finally,a forward-looking perspective on hydrogen medicine materials is demonstrated,which attempts to address the current clinical challenges in the field of hydrogen medicine.Especially,the development of small molecular bioprobes for in vivo H2 detection,the understanding of H2 pharmacokinetics and potential bioeffects,the exploration of the profound mechanisms underlying multifaceted biological behaviors of H2,the development of versatile hydrogen-delivering materials for the treatment of various intractable diseases,and the evaluation of potential long-term toxicity risk of both high-dose H2 and hydrogen〓〓delivering materials are highlighted.This Account is expected to illuminate the way for exploration of hydrogen medicine materials.展开更多
Impact statement We have developed the GReedy Accumulated strategy for Protein Engineering(GRAPE)to improve enzyme stability across various applications,combining advanced computational methods with a unique clusterin...Impact statement We have developed the GReedy Accumulated strategy for Protein Engineering(GRAPE)to improve enzyme stability across various applications,combining advanced computational methods with a unique clustering and greedy accumulation approach to efficiently explore epistatic effects with minimal experimental effort.To make this strategy accessible to nonexperts,we introduced GRAPE‐WEB,an automated,user‐friendly web server that allows the design,inspection,and combination of stabilizing mutations without requiring extensive bioinformatics knowledge.展开更多
文摘Objective: To investigate the effect and the mechanism of Shenfu injection (SFI, ) on the resuscitation from general anesthesia . Methods: Forty patients who received selective abdominal surgery with general anesthesia for 3-4 hrs and ASA grade Ⅰ-Ⅱ were divided into two groups, the trial group and the control group, 20 patients in each group. After being sent into the postanesthesia care unit (PACU), the trial group was treated with intravenous dripping of SFI 1.0 ml/kg and the control group was treated with intravenous dripping of equal volume of normal saline. All patients were observed in double blindly manner, the self ventilation recovery time, extubation time, the time of leaving PACU and their Glasgow coma scale (GCS) were recorded and compared. 2 ml of peripheral venous blood were taken to determine the plasma β-endorphin (β-EP) content at the time points of before (T1), 5min (T2), 15min (T3) and 30 min (T4) after dripping. Results: The self ventilation recovery time, extubation time and time of leaving PACU in the trial group were all shorter than those in the control group (P<0 01), the GCS in the trial group was better than that in the control group (P<0 01). The plasma content of β-EP raised gradually along the recovering of patients consciousness, as compared with the content before dripping (T1), it showed insignificant difference at time point T2 but significant difference at T3 and T4, comparison at the corres ponding time point showed that the content at T1 and T2 were similar in the two groups (P>0 05), but at T3 and T4, the content was higher in the trial group than that in the control group respectively (P<0 01). There was insignificant difference between T1 and before treatment ( P>0 05), but significant difference was found when compared T3, T4 and before treatment (P<0 01).Conclusion: SFI could accelerate the resuscitation after general anesthesia, the mechanism may be related with its action in raising plasma β-EP level.
文摘Objective: to analyze the clinical treatment of benign prostatic hyperplasia (BPH) symptoms and explore the efficacy of different surgical methods. Methods: during the study period, 82 male patients diagnosed and treated in the prostate department of our hospital were included as clinical analysis cases. The start time of the study was from April 2021. The data needed during the clinical study period were collected, and the relevant research plan was drawn up until April 2022. The selected patients were divided into groups according to their treatment methods. The number of patients in each group was 41:41, of which the control group was given plasma electrotomy and the study group was given plasma enucleation. The complications, clinical indexes, quality of life, urodynamics and ILEF-5 were compared between the two groups. Results: compared with the two groups, the quality of life in the study group was higher. Compared with the two groups, the control group had more complications. Compared with the urodynamic indexes of the two groups, the PVR index of the control group was (40.05 ± 3.69), the VMCC index was (337.36 ± 25.39), the Qmax index was (21.95 ± 1.24), the PVR index of the study group was (42.35 ± 4.22), the VMCC index was (349.54 ± 25.48), and the Qmax index was (23.25 ± 1.07), P < 0.05. Comparison of sexual function and erectile function scores between the two groups: the preoperative index of the study group was (24.58 ± 5.59) compared with that of the control group (23.97 ± 5.47), and there was no statistical significance, P > 0.05. After treatment, the index of the control group was (16.24 ± 5.47) compared with that of the study group (20.55 ± 5.69), and the score of the control group was lower. Compared with the clinical indexes of the two groups, the indexes of the control group were worse, P < 0.05. Conclusion: during the clinical treatment of benign prostatic hyperplasia, the patients were treated with different operations, and good results were achieved. During the treatment of plasma enucleation, the clinical related index were excellent.
基金support from the National Natural Science Foundation of China(52425309,82172078,U23A20690,82372104)Guang Dong Basic and Applied Basic Research Foundation(2024A1515030203)+2 种基金Shenzhen Science and Technology Program(RCJC20210706092010008,JCYJ20230807113918038)National Key Research and Development Program of China(2022YFB3804500)Natural Science Foundation of Top Talent of SZTU(GDRC202338).
文摘CONSPECTUS:Hydrogen medicine materials are defined as a new concept of biomedical materials specifically engineered to overcome critical challenges in hydrogen medicine,including exploration of biological effects and mechanisms of H2 by in vivo monitoring of H2 transportation,metabolism and transformation,enhancement of H2 therapeutic efficacy against various oxidative stress-related diseases by high-efficiency and site-specific delivery and controlled release of H2,etc.As the smallest and weakly reductive molecule,H2 exhibits some unique biological characteristics,including high tissue permeability,antioxidative stress(OS),anti-inflammation,antiapoptosis,antisenescence,pro-regeneration/pro-self-repairing,anticancer,antibiofilm,high bio-compatibility,and biosafety,holding a high value of biomedical applications.However,the related biological mechanisms are not very clear.Typically,multifaceted biological behaviors of H2 in varied pathological microenvironments,such as inflammation,cancer,and injured tissue,have not been well elucidated.Moreover,as a therapeutic agent,the pharmacokinetics of H2,involving absorption,biodistribution,metabolism,and excretion,has to be clarified before clinical application,which needs the development of hydrogen bioprobes to resolve.Based on high biosafety and therapeutic validity of H2,both hydrogen gas inhalator and hydrogen-rich water generator have been clinically approved for adjuvant therapy of some respiratory and digestive system diseases including chronic obstructive pulmonary disease(COPD),hyperuricemia,hyperlipemia,gastrelcosis and coprostasis,but they hardly realize effective delivery toward remote diseased focuses.Therefore,efficient,site-specific and controlled/sustained H2-delivering materials with high biosafety urgently need to be developed for improving the outcome of hydrogen therapy.Based on these unique advantages and unsolved key issues in hydrogen medicine,hydrogen medicine materials as an emerging interdisciplinary field have attracted increasing attention in recent years.In this Account,we present a brief overview of the recent advances of hydrogen medicine materials including hydrogen bioprobes and hydrogen-delivering materials(hydrogen carriers,hydrolytic hydrogen-generating materials,and catalytic hydrogen-generating materials),as well as their typical biomedical applications including targeted inflammation therapy,targeted tumor therapy,and local tissue repair/regeneration.Finally,a forward-looking perspective on hydrogen medicine materials is demonstrated,which attempts to address the current clinical challenges in the field of hydrogen medicine.Especially,the development of small molecular bioprobes for in vivo H2 detection,the understanding of H2 pharmacokinetics and potential bioeffects,the exploration of the profound mechanisms underlying multifaceted biological behaviors of H2,the development of versatile hydrogen-delivering materials for the treatment of various intractable diseases,and the evaluation of potential long-term toxicity risk of both high-dose H2 and hydrogen〓〓delivering materials are highlighted.This Account is expected to illuminate the way for exploration of hydrogen medicine materials.
基金supported by the National Key R&D Program of China(grant no.2021YFC2103600)the National Natural Science Foundation of China(31822002,32170033,and 32422001)+2 种基金the Key Research Program of Frontier Sciences(ZDBS‐LY‐SM014)the Biological Resources Program(KFJBRP‐009 and KFJ‐BRP‐017‐58)from the Chinese Academy of Sciences,the Informatization Plan of Chinese Academy of Sciences(CAS‐WX2021SF‐0111)the Youth Innovation Promotion Association CAS(2022086).
文摘Impact statement We have developed the GReedy Accumulated strategy for Protein Engineering(GRAPE)to improve enzyme stability across various applications,combining advanced computational methods with a unique clustering and greedy accumulation approach to efficiently explore epistatic effects with minimal experimental effort.To make this strategy accessible to nonexperts,we introduced GRAPE‐WEB,an automated,user‐friendly web server that allows the design,inspection,and combination of stabilizing mutations without requiring extensive bioinformatics knowledge.
